Octreotide‐Associated Biliary Tract Dysfunction and Gallstone Formation: Pathophysiology and Management

The American Journal of Gastroenterology

Volumn 90, Issue 7, 1995, Pages 1042-1052

  Redfern, Jan Stephanie ^a,b   Fortuner, William J ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

ACROMEGALY; BILE SECRETION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFECT; ENDOCRINE TUMOR; GALLBLADDER EMPTYING; GALLSTONE FORMATION; GASTROINTESTINAL TOXICITY; HUMAN; ODDI SPHINCTER; PANCREAS TUMOR; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

BILE; CHOLELITHIASIS; GALLBLADDER; GALLBLADDER EMPTYING; HUMAN; OCTREOTIDE; SOMATOSTATIN; SUPPORT, NON-U.S. GOV'T;

EID: 0029014727     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1995.tb09413.x     Document Type: Article

References (117)

1. Octreotide, a new somatostalin analogue
2. Octreolide. A review of ils pharmacodynamic and pharmacokinclie properties, and therapeutic potential in conditions associated with excessive pentidc secretion
3. Somatostatin and somatostatin like pep‐tides: Clinical research and clinical applications
4. Octreolide in the treatment of disorders of the gastrointestinal tract
5. Gastrointestinal hormones and careinoid syndrome
6. Potential gastrointestinal uses of somatostatin and its synthetic analogue octreotide
7. Clinical applications of somatoslatin
8. Somatostatin therapy
9. Reubi JC– the role of somatostatin analogs in the diagnosis and trealment of tumors
10. Growth hormone suppression and nonproliferalive diabetic retinopathy: A preliminary feasibility study
11. Therapoutic uses of gastrointestinal peptides
12. Effect of octreotide on gall stone prevalence and gall bladder molility in acromegaly
13. Prospective study of the long‐term effects of somatostatin analog (octreotidet on gallbladder finc‐tion and gallstone formation in Chinese acromegalic patients
14. Effects of long term octreolide on gall stone formation and gall bladder function
15. Effects sur la litho‐genése biliaire du traitement au long cours par octréolide (SMS 201–995). chez des patients acromégales
16. A prospective examination of octreolide‐indueed gall‐bladder changes in acrornegaly
17. Assessment of gall bladder dynamics, cholecystokinin release and the development of gallstones during octreotide therapy for acromegaly
18. Gallstones in acromegalic patients undergoing different treatment regimens
19. Gallbladder emptying and gallstone formation in acromegalics treated with octreotide
20. A long‐term dose‐response study of somatoslatin analogue (SMS 201–995, octreolide). in resistant acromegaly
21. Gallbladder emptying and gallstone formation its patients on long‐term octreotide
22. Long‐term treatment of 189 acromegalic palienls with the sonatostatin analog octrcotide. Results of the Interational Multicenter Acromegaly Study Group
23. Therapeutic cfficacy of the somatoslatin analog SMS 201–995 (octreotide) in acromegaly. Effects of dose and frequency and long‐term safety
24. Long‐term treatment of acromegaly with octreotide (Sandostatin) [discussion 30–1]
25. Chronic Sandostatin treatment and side effects in 30 subjects
26. Gastrointestinal side effects of octreutide during long term treatment of acromegaly
27. The French SMS 201–995 Acromegaly Study Group. Long term effect of incremental doses of the somatostatin analog SMS 201–995 in 58 acromegalic patients
28. Clinical and biochemical effects of incremental doses of the long‐acting somalostatin analogue SMS 201–995 in ten acromegalic patients
29. Octreotide treatment of acromegaly
30. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acrontegaly
31. Postprandial gallbladder molilily during long term treatment with the long‐acting somalostatin analog SMS 201–995 in acromegaly
32. Cholelithiasis and acromegaly: Therapeutic strategies
33. Gallbladder disease and cholecyslectomy rales are independently variable
34. The epidemiology of gallstone disease in Rome, Italy. Part 1. Prevalence data in men
35. Prevalence of gallstones in acromegalics untreated with somatostatin
36. Chronic treatment with a long‐acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis
37. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadcnomas
38. Complications of long‐acting somatostatin analogue therapy
39. Gallstones and treatment with octreotide for acromegaly
40. Are all oclreotide‐associated gallbladder stones cholesterol‐rich
41. Classification and pathogencsis of gallstones
42. Gallstones: An update
43. Cholesterol gallstone formation. II. Pathobi‐ology and palhomechanics
44. Correlation of cholecystokinin receptors with gallbladder contractility in patients with gallstones
45. Inositol triphosphate restores impaired human gallbladder motility associated with cholesterol stones
46. Gallbladder mucin as a pronucleating agent for cholesterol monohydratc crystals in bile
47. Whither biliary sludge
48. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis
49. Role of gallbladder mucin in pathophysiology of gallstones
50. Effects of prostaglandins on motiliiy of gallbladders removed from patients with gallstones
51. Aspirin prevention of cholesterol gallstone formation in prairie dogs
52. Why docs somatostatin cause gallstones
53. Effects of somatostatin on gallbladder emptying
54. Gallbladder and gastrointestinal hormone responses to meal ingestion during long‐term Treatment with SMS–201–995 in acromegaly
55. Effect of small doses of somalostatin analog, octreotide, on gallbladder contractility in normal Clinese‐adults
56. Changes in biliary dynamics and the development of gallstones during octreotide therapy for acromegaly
57. Gallbladder emptying in acromegalic patients treated by octreotide
58. Gallbladder molility and gallstones in acromegaly
59. Effect of somatostatin on gallbladder volume and small intestinal motor activity in humans
60. Effects of atropine. proglumide, and somaioslalin analogue (SMS 201–995). on bomb‐esin‐induced gallbladder contraction and CCK secretion in humans
61. Effect of the somatostatin analogue Sandostatin (SMS 201–995). on gastrointestinal, pancreatic and biliary function and hormone release in normal men
62. Effect of somatostatin and thyrolropin‐releasing hormone on cholecystokinin‐induced gallbladder emptying
63. Effects of graded doses of somatostatin on gallbladder emptying and pancreatic enzyme output after oral glucose in man
64. Inhibition by somatostatin of pancreatic juice and enzyme secretion and gallbladder contraction induced by secretirt, cholecystokinin‐pancreozymin and carbachol administration
65. Nifedipine inhibits choiceys‐tokinin‐induced gallbladder contraction
66. Pharmacology of biliary tract
67. Effects of cholecys‐tokinin‐octapeptide on the human gallbladder both in vivo and in vitro
68. Somatostatin inhibits the release of aceiylcholine induced electrically in the myentrtc plexus
69. Contractility of human gallbladder muscle in vitro
70. Hepatic bile formation (first of two parts)
71. Hepatic bile formation (second of two parts)
72. Bife secretion in man. The effects of somaloslalin, vaso‐active intestinal peptide and secrelin
73. Effects in somatostatin on hepatic bile formation
74. Cholestatic action of somatostatin in the rat: Effect on the different fractions of bile secretion
75. Pharmacologic effect of somaloslalin on bile formal ion in the dog. Enhanced duclular reabsorption as the major mechanism of anticholeresis
76. Hormonal contributions to biliary secretion
77. Effect of somatostatin and bombesin on secretin‐stimulated duclular bile flow in dogs
78. Inhibition of glucagon or secretin stimulated bile flow by somatostalin
79. Pharmacological effect of somaiosialin on bile secretion in man
80. Bile concentration is key factor for nuclcalion of cholesterol crystals and cholesterol saturation index in gallbladder bile of gallstone pa‐tients
81. The role of bile composition and physical chemistry in the pathogenesis of octreotide‐associaled gallbladder stones
82. Slow intestinal transit and gallstone formation
83. The influence of somatoslalin on gallbladder response to intraduodenad acid and autonomic nerve stimulation in the cal
84. Octreolide inhibits the effect of vasoactive intestinal peptide (VIP) on gallbladder absorption
85. Deoxycholic acid and the pathogenesis of gallstones
86. The roles of biliary deoxycholic acid (DCA). and vesicular cholesterol (CH). in the palhogenesis of CM gallbladder stones (GBS), [abstract]
87. Windowless energy dispersive x‐ray microanalysis of gallstones
88. Somatostatin inhibits sphincter of Oddi motility
89. Octreotide inhibits and CCK stimulates prairie dog sphincter of Oddi motilily via noncholinergie pathways
90. Effect of somatostalin analog octrcotide on human sphincter of Oddi
91. Pathogenesis and treatment of gallstones
92. Asymptomatic gallstones: Definition and treatment
93. Asymptomatic gall‐siones revisited
94. Hepatic cholesterol and bile acid metabolism in subjects with gallstones: Comparative effects of short‐term feeding of chenodeoxycholic and ursodeoxycholic acid
95. Restoration of gallbladder contractility after withdrawal of long‐term octreolide therapy in ac‐romegalic patients
96. Postprandial gallbladder molility and plasma ehulecystokinin al regular lime intervals after injection of oetreotide in acromegalics on long‐term treatment
97. Gallstones during oetreotide therapy
98. Prevention of gallstone recurrence by non‐stcroidal ami‐inflammatory drugs
99. One gram of aspirin per day does not reduce risk of hospitalization for gallstone disease
100. Effects of ursodeoxycholic acid and aspirin on the formation of lilhogenic bile and gallstones during loss of weight
101. Aspirin does not inhibit cholesterol cholelithiasis in two established animal models
102. Cholccystokinin prevents parenteral nutrition induced biliary sludge in humans
103. Postprandial gallbladder motilily. CCK and PP release during intermittent and continuous octreolide therapy in acromegaly: Implications for prevention of gallstones
104. Gallbladder function in acromegalic patients taking long‐term octreotider: Evidence of rebound hypermotilily on cessation of treatment
105. Biliary colic on abrupt with‐drawal of octreolide
106. Cholescintigraphic study of effect of somatostalin analog, oetreotide, on bile secretion and gallbladder emptying in normal subjects
107. Effects of substance P and somalostatin on taurocholate‐stabilized and CCK‐ or secrclin‐induced choleresis in the anesthetized dog
108. Somatostatin suppression of canine fasting bile secretion
109. Effect of somatostatin on determinants of bile flow in unanesthelized dogs
110. Inhibition of basal and meal‐stimulated cholcresis by somatostutin
111. Somatostalin inhibits the effect of secretin on bile flow and on hepalic bilirubin transport in the rat
112. Is somatostatin a directly acting cholestatic hormone
113. Effects of gastrointotinal peptide on formation of gallstone in guinea pigs